Wang T, Shen YY. Rare ROS1-CENPW gene in pancreatic acinar cell carcinoma and the effect of crizotinib plus AG chemotherapy: A case report. World J Clin Cases 2023; 11(24): 5823-5829 [PMID: 37727713 DOI: 10.12998/wjcc.v11.i24.5823]
Corresponding Author of This Article
Yi-Yu Shen, MCh, Chief Physician, Doctor, Surgeon, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, No. 1518 Huancheng North Road, Jiaxing 314051, Zhejiang Province, China. syjdr@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 26, 2023; 11(24): 5823-5829 Published online Aug 26, 2023. doi: 10.12998/wjcc.v11.i24.5823
Rare ROS1-CENPW gene in pancreatic acinar cell carcinoma and the effect of crizotinib plus AG chemotherapy: A case report
Tao Wang, Yi-Yu Shen
Tao Wang, Graduate School, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Yi-Yu Shen, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314051, Zhejiang Province, China
Author contributions: Wang T analyzed the data and wrote the manuscript; Shen YY conducted data collection, analysis, and chart production; All authors have read and approved the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi-Yu Shen, MCh, Chief Physician, Doctor, Surgeon, Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Jiaxing University, No. 1518 Huancheng North Road, Jiaxing 314051, Zhejiang Province, China. syjdr@163.com
Received: June 13, 2023 Peer-review started: June 13, 2023 First decision: July 7, 2023 Revised: July 16, 2023 Accepted: July 28, 2023 Article in press: July 28, 2023 Published online: August 26, 2023 Processing time: 73 Days and 0.2 Hours
Abstract
BACKGROUND
This is the first report of an ROS1-CENPW fusion gene in pancreatic malignancies.
CASE SUMMARY
A 77-year-old woman with a pancreatic tumor and multiple liver metastases was admitted to our hospital. Genetic testing revealed the presence of the ROS1-CENPW fusion gene, a rare fusion gene that has not been previously reported in the field of pancreatic cancer. The patient received crizotinib plus AG (albumin paclitaxel plus gemcitabine) chemotherapy. After treatment, the patient’s condition stabilized, and her prognosis was good.
CONCLUSION
The ROS1-CENPW gene treatment regimen used in this case is an excellent treatment option that provides new hope for patients with advanced pancreatic cancer and similar genetic mutations. To date, owing to the rarity of the ROS1-CENPW fusion gene, our team has encountered only a single case. Therefore, the efficacy of crizotinib plus AG chemotherapy in patients with pancreatic acinar cell carcinoma harboring the ROS1-CENPW fusion gene requires further validation.
Core Tip:ROS1-CENPW is a novel fusion gene locus in pancreatic acinar cell carcinoma that has not been previously reported. We detected this rare fusion gene in a 77-year-old female patient with pancreatic acinar cell carcinoma. We adopted the treatment regimen of crizotinib combined with AG chemotherapy (gemcitabine 1000 mg/m2 plus albumin paclitaxel 125 mg/m2). A good therapeutic effect was achieved.
